In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, ...

Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research ...

Bio-Techne Corporation (NASDAQ:TECH) is one of the most profitable biotech stocks to invest in now. On July 9, TD Cowen analyst Daniel Brennan initiated a new Buy rating on Bio-Techne Corporation ...

Shares of Bio-Techne Corp. slid 3.36% to $50.27 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index rising 0.14% to 6,305.60 and the Dow Jones ...

The FDA has granted Breakthrough Device Designation to Bio-Techne's (NASDAQ:TECH) ExoDx Prostate IntelliScore (EPI) test. Breakthrough Device status provides for more intensive guidance on development ...

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...

(RTTNews) - Gemini Bioproducts, LLC, a supplier of cell culture reagents and process liquids and healthcare private equity firm BelHealth Investment Partners, LLC announced acquisition of selected ...

Visualizes functional protein-protein interactions directly within fixed tissue at subcellular resolution Enables simultaneous detection of protein proximity, RNA, and proteins on the same tissue ...

Bio-Techne Corp. TECH has launched a highly sensitive ESR1 mutation monitoring assay through its Asuragen brand. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) ...

Shares of Bio-Techne Corp. slid 3.66% to $51.26 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.05% to 6,584.29 and Dow Jones ...